

- **Name: Dae Sik Kim**

- **Affiliation/Current Position**

: Korea University Guro Hospital,  
Division of Oncology & Hematology, Department of Internal Medicine  
/ Associate professor

- **Country: Republic of Korea**

- **ICKSH2022 Presentation Title**

: Recent Advances in Treatments of Immune Thrombocytopenia

- **Educational Background**

: Mar. 1998 – Feb. 2004: Korea University School of Medicine, Seoul, Korea: M.D.

Sep. 2006 – Aug. 2008: Korea University Graduate School, Seoul, Korea: M.Sc.

Mar. 2012 – Aug. 2014: Korea University Graduate School, Seoul, Korea: Ph.D.

- **Professional Experiences:**

Mar. 2004 – Feb. 2005: Internship in Korea University Hospital, Seoul

Mar. 2005 – Feb. 2009: Residency in Internal Medicine,  
Korea University Hospital, Seoul

Mar. 2009 – Apr. 2012: Military service (Korean Army, army doctor)

May 2012 – Feb. 2014: Clinical Instructor, Division of Oncology & Hematology,  
Department of Internal Medicine, Guro Hospital,  
Korea University School of Medicine, Seoul

May 2014 – Aug 2016: Clinical Assistant Professor, Division of Oncology &  
Hematology, Department of Internal Medicine,

Guro Hospital, Korea University School of Medicine, Seoul

Sep 2016 – Aug 2019: Assistant Professor, Division of Oncology & Hematology,  
Department of Internal Medicine, Guro Hospital,  
Korea University School of Medicine, Seoul

Sep 2019 ~ : Associate Professor, Division of Oncology & Hematology,  
Department of Internal Medicine, Guro Hospital,  
Korea University School of Medicine, Seoul

### • Professional Organizations

Member of Korean Association of Internal Medicine

Member of Korean Society of Hematology (KSH)

Member of Korean Society of Hematopoietic Stem Cell Transplantation

Steering Committee Member of committee of histiocyte Society, KSH

Steering Committee Member of Youth Commission, KSH

### • Main Scientific Publications:

1. Lee BH, Kang KW, Kim DS et al. (2021) Prediction Model for Cereblon Expression in Bone Marrow Plasma Cells Based on Blood Markers in Multiple Myeloma Patients. *Front. Oncol.* 11:687361.

2. Hong JS, Lee YJ, Kim DS et al. (2021) Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity. *Blood Res*;56(2):102-108

3. Na YJ, Kim DS, Choi CW et al. (2021) Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells. *Korean J Intern Med* Mar;36(Suppl 1):S196-S206

4. Lee JH, Park Y, Kim DS et al. (2021) Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial. *Ann Hematol* Aug;100(8):2051-2059
5. Kang KW, Kim DS, Kim BS (2020) Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents. *Ther Adv Hematol* Vol. 11: 1–14
6. Yu ES, Jeon MJ, Kim DS, et al. (2020) The role of platelet function analyzer-200 in predicting perioperative bleeding risk. *Korean J Intern Med* Sep;35(5):1199-1209.
7. Song GY, Kim DS, Yang DH. et al. Prognostic significance of interim PET/CT response for the treatment of advanced-stage marginal zone lymphoma in the post-rituximab era. *Sci Rep* Jul 15;10(1):11649
8. Kang KW, Kim DS, Kim BS et al. (2020) Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim *Cancer Med* 2020 Sep;9(17):6102-6110
9. Jeon MJ, Yu ES, Kim DS, et al. (2020) Immature platelet fraction based diagnostic predictive scoring model for Immune Thrombocytopenia. *Korean J Intern Med*, Jul;35(4):970-978.
10. Kim DS, Park Y, Jeon MJ, et al. (2019) Single-dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma. *J Clin Apher* 34:579-588.
11. Jung S-H, Kim DS, Yang D-H, et al. (2019) Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party. *Ann Hematol* 98:151–158.